Antithrombotic effect of the copper-aspirin complex (dimeric copper(II) bis (o-acetoxybenzoate) was evaluated in the model of venous thrombosis; its effects on platelet-neutrophil adhesion were investigated by use of rosette assay. The results showed that the intragastrically administered copperaspirin complex (5, 7, and 10 mg kg"l) dose-dependently lowered the wet and dry thrombus weight; it significantly decreased the binding of araehidonic acid-activated 
RESULTS AND DISCUSSION
In vehicle group, the wet and dry thrombus weight were 9.9 +/-1.8 and 4.1 +/-0.5 mg, respectively.
Intragastri,c, administratiOno 5o, f , _ aspirin,,20 mg / kg significantly reduced the wet and dry thrombus weight to 2.2 _ 1.3 and 1.0 +/-mg ( P < 0.01 vs vehicle). The copper-aspirin complex administered intragastrically at 5,,7, and 10 mg / kg markedly decreased the wet thrombus weight to 4.9 +/-2.1", 2.7 +/-1.9"*, and 2.3 +/-1.0" mg, and suppressed the dry thrombus weight to 1.5 +/-0.6", 1.2 +/-0.7", and 0.8 +/-0.6"* mg P < 0.01 vs vehicle), respectively. (Table I) Our previous research indicated that the copper aspirin complex had a more potent antiplatelet activity [3] . But all this work was focused on platelets alone, not involved in neutrophils.
Platelet-neutrophil adhesion may play key factors in thromboembolic processes and adhesion of these two kinds of blood cells is involved in the process of thrombomodulation [1] . Activation of platelets increases neutrophil adhesion to foreign surfaces, neutrophile aggregation, lysosomal enzyme release, etc. Platelet-derived products are able to promote neutrophil chemotaxsis, enzyme release, and phagocytosis and to inhibit oxidative burst [6] . On the other hand, neutrophil-derived products can enhance platelet aggregation, semtonin release and cytoplasmic Ca -+ movement [7] . It is necessary, therefore, to study an antithrombotic drug based on its influence on multiple cellular interactions.
In venous thrombosis, the copper-aspirin complex showed a dose-dependently inhibition, seven mg kg 1 antithrombotic activity than aspirin due to its higher activity on platelet-neutrophil adhesion.
In conclusion, the copper-aspirin complex may be more potential in treating thromboembolic diseases because of its lower gastrointestinal side effects.
